Human Papillomavirus Vaccine Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Human Papillomavirus Vaccine Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The human papillomavirus (HPV) vaccine market is expected to register a CAGR of nearly 7.5% during the forecast period.

The pandemic not only impacted the work of researchers and pharmaceutical companies, but also the diagnosis and treatment of various diseases caused by the HPV virus, along with a halt in HPV vaccination programs worldwide. As per a research study published in March 2021, titled “Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening”, of the total respondents, 74.0% of respondents were experiencing supply shortage, 54.0% reported a shortage of personnel, and 33.0% reported delays in ordering equipment. The same study concluded that the demand for SARS-CoV-2 testing competed with HPV testing, compounded by a shortage of staff. This was a major challenge for existing laboratory services and settings keen to implement HPV-based screening. Furthermore, during the COVID-19 pandemic, cervical cancer screening visits and HPV infection rates have decreased dramatically. HPV transmission has also decreased after strict lockdown. For instance, a study titled “Impact of COVID-19 Outbreak on the Gynecological Outpatients HPV Infection Rate in Wuhan, China: A Retrospective Observational Study,” published in April 2022, collected data regarding HPV and cervical cancer screening results of outpatients from gynecological clinics of a tertiary hospital from 1 December 2018 to 31 December 2020 in Wuhan. It concluded that there was a 50.0% decrease in HPV screening visits and a 10.0% decrease in HPV infection rates throughout the pandemic when compared with the numbers collected before the pandemic. Therefore, the pandemic had a significant impact on the market under study, but market growth is anticipated to recover during the forecast period.

The major factors for the growth of the human papillomavirus (HPV) vaccine market include the approval of new HPV vaccines, and increasing initiatives by government & private organizations for early screening & vaccination. The increasing incidence of HPV-associated cancers such as anal, oropharynx, and genital parts and the growing demand for HPV vaccines to help reduce infections are factors likely to bolster the healthy growth of the market in the forthcoming years.

The approval of the new vaccine by the regulatory bodies makes vaccines more readily accessible for immunization or vaccination, which is anticipated to expedite market expansion. For instance, in September 2021, MSD Pharmaceuticals India launched the gender-neutral Human Papillomavirus or HPV Vaccine, which is expected to help reduce HPV-related disease burden among both girls and boys. Such types of initiatives are expected to boost the growth of the market. Additionally, in October 2021, a USD 11.7 million grant was given to a UNC Gillings School of Global Public Health researcher to assist healthcare professionals in increasing adolescent acceptance of the HPV vaccine. According to a researcher, the human papillomavirus (HPV) vaccine, which is typically administered during adolescence, could prevent more than 32,000 cancer cases in the United States each year. Instances like these encourage people to get the HPV vaccine to protect themselves from diseases.

The rising government initiatives are expected to propel the overall growth of the market over the forecast period. In high-income countries, programs are in place to enable girls to be vaccinated against human papillomavirus (HPV) and women to get screened regularly and treated adequately. Screening allows pre-cancerous lesions to be identified at stages that can easily be treated. For instance, in January 2021, the United States Department of Health and Human Services launched the "HPV VAX NOW" campaign with the long-term goal of increasing human papillomavirus (HPV) vaccination rates among young adults aged 18–26 years. The campaign will specifically target young adults and healthcare providers in Mississippi, South Carolina, and Texas, as these are states in the United States with the lowest HPV vaccination rates. Therefore, it is anticipated that greater awareness of HVP vaccination will spur market growth.

However, stringent regulation is likely to hinder market growth over the forecast period.

Key Market TrendsCervical Cancer Segment is Expected to Hold the Largest Market Share Over the Forecast Period

The cervical cancer segment accounted for the largest share and is expected to be dominant in the market during the forecast period. Nearly all instances of cervical cancer are caused by human papillomavirus (HPV). Major factors driving the growth of the market segment include the increasing burden of cervical cancer, supported by government initiatives for early screening and vaccination, and rapid approval for vaccines. HPV vaccines can prevent most cases of cervical cancer if the vaccine is given before the patients are exposed to the virus. Also, there are highly sensitive and specific molecular tests now available to identify from DNA, the high-risk HPV types, in cervical cancer screening.

According to the Globocan 2020 report, cervix uteri cancer was the seventh most diagnosed cancer around the world with about 604,127 new cases in 2020 and this number is projected to increase to 847,306 cases by 2040, with the highest prevalence in the Asia region. Thus, with the high burden of cervical cancer and its increasing prevalence around the world, the demand for preventive measures is expected to increase, which is anticipated to boost the growth in the studied market over the forecast period.

Furthermore, according to the World Health Organization’s (WHO) Factsheet, titled ‘Human papillomavirus (HPV) and cervical cancer,’ updated in November 2020, comprehensive cervical cancer control include primary prevention (vaccination against HPV), secondary prevention (screening and treatment of pre-cancerous lesions), tertiary prevention (diagnosis and treatment of invasive cervical cancer) and palliative care. Such guidelines by health authorities also drive the growth of the market. Similarly, in November 2021, The World Health Organization (WHO) announced a global commitment to end cervical cancer, and the Australian Government has committed USD 5.8 million to support the pledge. The National Cervical Screening Program promotes a quick test done every five years to check for HPV, a common infection that almost always results in cervical cancer. This test is done before any cancerous cells manifest.

Thus, owing to the rising cases of cervical cancer the market is expected to witness high growth over the forecast period.

North America is Expected to Hold Largest Market Share over the Forecast Period

The United States is expected to be the largest HPV vaccine market owing to the presence of better healthcare infrastructure. Major factors driving the growth of the market in the United States include the well-established healthcare industry, the rising burden of cancers caused by papillomavirus, and technological advancement supported by the government and regulatory authorities.

According to the American Cancer Society’s article, titled ‘‘Key Statistics for Cervical Cancer,’’ updated in January 2021, about 14,480 new cases of invasive cervical cancer were expected to be diagnosed in 2021 and about 4,290 women’s deaths were predicted in the United States. Therefore, such rising cases are expected to boost the growth of the market in the United States.

Furthermore, approvals by regulatory authorities also drive the growth of the market. For instance, in June 2020, Merck received the United States Food and Drug Administration (FDA) approval for an expanded indication for GARDASIL9 for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58. Higher sales and value of Gardasil along with rapid adoption of human papillomavirus vaccines across the region will boost development in the region.

Thus, all aforementioned factors such as growing awareness about vaccination and product launches are expected to boost the market growth in the North American region over the forecast period.

Competitive Landscape

The market studied is a consolidated market owing to the presence of a few major market players. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known including Merck & Co., Inc., GlaxoSmithKline plc., Serum Institute of India Pvt. Ltd., and Wantai BioPharm among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.